Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology

Metastatic Cancer

California

Duarte : City of Hope New!

PHII-80 PHL-051 NCI #7502: A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas

Santa Monica : Premiere Oncology

A Phase 1 Study of STA-9090, Administered Once-Weekly in Patients with Solid Tumors

Santa Monica : Premiere Oncology

A Phase I Study of Single Agent LY2584702 in Patients with Advanced or Metastatic Cancer

Florida

Aventura : South Florida Medical Research

Phase II, Clinical Trial For Patients with Prostate Cancer or Breast Cancer with Metastatic Disease

Gainesville : Gainesville Hematology/ Oncology Associates

A Randomized Phase III Trial of Cetuximab, Bevacizumab and Biweekly Infusional 5-FU/Leucovorin (FOLF-CB) versus Oxaliplatin, Bevacizumab, and Biweekly Infusional 5-FU/Leucovorin (Bev-FOLFOX) in First-line Treatment of Metastatic Colorectal Cancer

Gainesville : Gainesville Hematology/ Oncology Associates

A Randomized, Phase 2B Study of Sunitinib Plus Oxaliplatin, 5-FU, and Leucovorin (FOLFOX)versus Bevacizumab Plus FOLFOX as First-line Treatment in Patients with Metastatic Colorectal Cancer

Illinois

Centralia : Southern Illinois Hematology/Oncology

This is a Phase 2 study to evaluate the efficacy and safety of NKTR-102 (a pegylated Irinotecan) in patients with breast cancer.

Kentucky

Louisville : Norton Health Care

This is a Phase 2 study to evaluate the efficacy and safety of NKTR-102 (a pegylated Irinotecan) in patients with breast cancer.

Massachusetts

Boston : Massachusetts General Hospital Cancer Center

An open-label dose escalation study of patients with solid tumors treated with STA-9090

Boston : Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center

An open-label dose escalation study of patients with solid tumors treated with STA-9090

Boston : Dana Farber Cancer Institute

An open-label dose escalation study of patients with solid tumors treated with STA-9090

Michigan

Detroit : Karmanos Cancer Institute Wayne State University

An open-label dose escalation study of patients with solid tumors treated with STA-9090

New York

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

A Pilot Feasibility Study of a Low Carbohydrate Diet In patients with Advanced Cancer. {Also known as the RECHARGE Trial (REduced CarboHydrates Against REsistant Growth Tumors).}

Manhasset : Biomedical Research Alliance of New York

Metastatic Cancer to the Brain - Adults

Ohio

Kettering : US Oncology Dayton Oncology and Hematology, P.A.

A Phase 1 Study of STA-9090, Administered Once-Weekly in Patients with Solid Tumors

Australia

BEDFORD PARK, SA : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Campbelltown, NSW : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Camperdown, NSW : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

CONCORD, NSW : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Greenslopes, QLD : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Liverpool, NSW : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Austria

Graz : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Linz : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Salzburg : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Wien : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Belgium

Bonheiden : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Leuven : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Finland

Helsinki : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Turku : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

France

Colmar : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Paris : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Reims : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Rouen : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Germany

Berlin : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Essen : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Halle : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Leverkusen : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Magdeburg : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Mannheim : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Muenchen : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Potsdam : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Various Cities : Research Sites

This is a multi-national, double-blind, placebo controlled study in patients with locally advanced or metastatic breast cancer.

Italy

Ancona : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Genova : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Livorno : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Sassari : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Various Cities : Research Sites

This is a multi-national, double-blind, placebo controlled study in patients with locally advanced or metastatic breast cancer.

Korea

Gyeonggi-do Gyeonggi-do : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Seoul : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Seoul : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Seoul : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Seoul : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Lithuania

Vilnius : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Vilnius : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Norway

Oslo : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Oslo : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Stavanger : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Tromso : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Peru

Lima : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Lima : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Poland

Various Cities : Research Sites

This is a multi-national, double-blind, placebo controlled study in patients with locally advanced or metastatic breast cancer.

Portugal

Coimbra : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Coimbra : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Lisboa : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Porto : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Russian Federation

Various Cities : Research Sites

This is a multi-national, double-blind, placebo controlled study in patients with locally advanced or metastatic breast cancer.

Spain

Barcelona : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Barcelona : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Cordoba : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Jaen : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Madrid : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Madrid : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Sevilla : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Valencia : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Sweden

Göteborg : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Karlstad : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Stockholm : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Sundsvall : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Uppsala : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Taiwan

Chiayi : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Tainan : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Taipei : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Taoyuan : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

United Kingdom

London : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

London : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Manchester : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Surrey : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

West Midlands : Research Site

A Phase II/III Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.